Alphatec Misses Its Own Third-Quarter Plan On Biologics, Cuts Full-Year Revenue Outlook To $862 Million
Hardware sales rose 17% and new surgeon users 25%, but weak biologics attachment left the spine-device maker short of its own target.
Alphatec, which makes devices for spine surgery, said its third-quarter revenue of $221 million, up 13% from a year earlier, fell short of its own expectations because surgeons attached fewer biologics products to procedures. Chairman and CEO Pat Miles said the company "own[s]" the shortfall, in results released Thursday.
Strong procedures, weak biologics
Surgical revenue rose 14% to $202 million, up $25 million from a year earlier. Surgical hardware contributed $26 million of that growth and climbed 17%.
Miles said the miss came "primarily due to lower biologics attachment," meaning bone graft products sold alongside procedures. He said improving biologics performance is "a clear priority," even as case volumes grew about 20% and new surgeon adoption rose 25%.
Miles added that disciplined biologics execution is required to turn procedures into full revenue, and that it underpins the longer-term opportunity with OsteoAdapt (Theradaptive).
Profit improved, cash fell
Alphatec, based in Carlsbad, California, sells spinal implants, instruments and an imaging and robotics platform to spine surgeons. The company posted a net loss of $5.5 million, compared with a $28.6 million loss a year earlier. Adjusted net income was $15 million.
Adjusted EBITDA reached $38 million, a 17.3% margin, up 400 basis points (four percentage points) from the year-ago quarter. Free cash flow was $6 million.
Cash stood at $80 million at September 30, down from about $161 million at the end of 2025. Short-term debt fell to $5.3 million from $64.5 million over the same stretch.
The reset 2026 outlook
For 2026, the company now expects revenue of about $862 million, including about $789 million of surgical revenue and about $73 million from its EOS imaging business. That implies roughly 13% total growth and about 15% surgical growth.
It also expects adjusted EBITDA of about $137 million and free cash flow of about $10 million for the year.
Whether biologics attachment recovers will decide if Alphatec reaches the $862 million it now guides to.
Sources
- 8-K Filing — Alphatec Holdings, Inc. (ATEC) — SEC EDGAR
- Exhibit atec-ex99_1.htm — Alphatec Holdings, Inc. 8-K exhibit — SEC EDGAR
- ATEC Reports Third Quarter Financial Results — businesswire.com